

**SUPPLEMENTARY INFORMATION:** On Wednesday, November 8, 1995, there was published in the Federal Register, 60 FR 56338, a proposed consent agreement with analysis In the Matter of The Stop & Shop Companies, Inc., et al., for the purpose of soliciting public comment. Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to divest, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45)

Donald S. Clark,

Secretary.

[FR Doc. 96-12706 Filed 5-20-96; 8:45 am]

BILLING CODE 6750-01-M

[Dkt. C-3244]

### **West Point-Pepperell, Inc.; Prohibited Trade Practices and Affirmative Corrective Actions**

**AGENCY:** Federal Trade Commission.

**ACTION:** Set aside order.

**SUMMARY:** This order reopens a 1988 consent order—which required West Point to divest certain towel and sheet manufacturing facilities and prohibited West Point, for 10 years, from making certain acquisitions in the sheet and towel industries without prior Commission approval—and sets aside the consent order pursuant to the Commission's Prior Approval Policy Statement, under which the Commission presumes that the public interest requires setting aside the prior approval requirements in outstanding merger orders and making them consistent with that policy.

**DATES:** Consent order issued December 14, 1988. Set aside order issued October 4, 1995.<sup>1</sup>

**FOR FURTHER INFORMATION CONTACT:** Daniel Ducore, FTC/S-2115, Washington, D.C. 20580, (202) 326-2526.

**SUPPLEMENTARY INFORMATION:** In the Matter of West Point-Pepperell, Inc. The prohibited trade practices and/or

corrective actions are removed as indicated.

Authority: Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interpret or apply sec. 5, 38 Stat. 719, as amended; sec. 7, 38 Stat. 731, as amended; 15 U.S.C. 45, 18)

Donald S. Clark,

Secretary.

[FR Doc. 96-12707 Filed 5-20-96; 8:45 am]

BILLING CODE 6750-01-M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Centers for Disease Control and Prevention**

#### **Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Idaho National Engineering Laboratory Health Effects Subcommittee**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announce the following meeting.

*Name:* Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Idaho National Engineering Laboratory Health Effects Subcommittee (INEL).

*Times and Dates:* 8 a.m.–5 p.m., June 5, 1996; 7 p.m.–9 p.m., June 5, 1996; 8 a.m.–12:15 p.m., June 6, 1996.

*Place:* Quality Inn Pocatello Park Hotel, 1555, Pocatello Creek Road, Pocatello, Idaho 83201.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose:* The Subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community, American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at respective DOE sites. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

*Matters To Be Discussed:* Agenda items include: the Biological Effects of Radiation—Radionuclides releases other than plutonium that could cause health effects, declassification issues, high efficiency particulate air filters, environmental monitoring—past and present, discussion of Phase I, and other

than radionuclides present at INEL (e.g., chemicals: most toxic and carcinogenic).

Agenda items are subject to change as priorities dictate.

*Contact Persons For More*

*Information:* Arthur J. Robinson or Nadine Dickerson, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, M/S F-35, Atlanta, Georgia 30341-3724, telephone 770/488-7040, FAX 770/488-7044.

Dated: May 15, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-12686 Filed 5-20-96; 8:45 am]

BILLING CODE 4163-18-M

## **Food and Drug Administration**

[Docket No. 92N-0438]

### **Worldwide Biologicals, Inc.; Revocation of U.S. License No. 832-003**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the revocation of the establishment license (U.S. License No. 832-003) and the product license issued to Worldwide Biologicals, Inc., for the manufacture of Source Plasma. A notice of opportunity for a hearing on a proposal to revoke the licenses was published in the Federal Register of March 22, 1993. Worldwide Biologicals, Inc., subsequently requested a hearing. In a separate legal proceeding, the responsible head of Worldwide Biologicals, Inc., voluntarily surrendered U.S. License No. 832-003 pursuant to a plea agreement with the United States Attorney for the Southern District of Ohio and the Office of Consumer Litigation, United States Department of Justice, which represented FDA in the proceeding. In light of Worldwide Biologicals, Inc.'s, surrender of its license, the firm's request for an opportunity for a hearing on the issue of license revocation became moot. FDA, therefore, proceeded to revoke the licenses.

**DATES:** The revocation of the establishment license (U.S. License No. 832-003) and product license became effective September 29, 1994.

**FOR FURTHER INFORMATION CONTACT:** Stephen M. Ripley or Tracey H. Forfa, Center for Biologics Evaluation and Research (HFM-635), Food and Drug Administration, 1401 Rockville Pike,

<sup>1</sup> Copies of the Consent Order and Set Aside Order are available from the Commission's Public Reference Branch, H-130, 6th Street and Pennsylvania Avenue NW., Washington, D.C. 20580.